Post marketing study (PMS) about specific immunotherapy with a grass allergy immunotherapy tablet (AIT)

Post marketing study (PMS) about specific immunotherapy with a grass allergy immunotherapy tablet (AIT) Since 2007 the sublingual allergy immunotherapy tablet (AIT) GRAZAX (R) has been available in Austria for the causal treatment of grass pollen induced rhinoconjunctivitis. The effectiveness of the AIT has been demonstrated in multiple clinical studies. Additional data on the safety and tolerability of the grass AIT were collected in a post marketing study with 577 grass-allergic-patients treated by 73 Austrian physicians. This non-interventional study demonstrated a high level of treatment adherence of 80% after I year of treatment. Additionally 90% of the patients treated with AIT reported an improvement of their allergy symptoms. The treatment was overall very well tolerated the majority of the reported drug adverse reactions (92.4%) were transient, mild to moderate reactions located mainly in the oral cavity or the throat. There were no treatment-related serious adverse events reported in the study. These results on the safety, practicability and acceptance of the grass tablet confirm that AIT is appropriate for home administration.